Search results
Results From The WOW.Com Content Network
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [ 7][ 8]
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
If approved, it would be the first vaccine for tuberculosis in more than a century after the BCG vaccine. [1] [2] It was initially developed by GSK plc and funded by non-profits and governments due to the limited commercial potential of tuberculosis vaccines, which are mainly needed in poor countries.
The vaccines are the first approved to prevent RSV, which causes around 14,000 deaths in adults aged 65 and older in the U.S. annually, according to government estimates. US CDC OKs use of new ...
(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot ...
GSK shares rose 1.3% on Thursday. RSV is a leading cause of pneumonia in toddlers and the elderly and GSK's shot, branded Arexvy, "will be more than a billion pounds in its first year, (it) has ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The MMR vaccine is a mixture of live weakened viruses of the three diseases. The MMR vaccine was developed by Maurice Hilleman. It was licensed for use in the US by Merck in 1971. Stand-alone measles, mumps, and rubella vaccines had been previously licensed in 1963, 1967, and 1969, respectively.